Biotech Kite Pharma (KITE) acknowledged Monday that a patient in one of its clinical trials died, but said the death was unrelated to its drug candidate. Kite’s stock was pounded last week, falling 9% on Thursday and 3.5% on Friday, by a rumor of a patient death in the phase one trial of its candidate KTE-C19 in diffuse large B-cell lymphoma. On Monday, the company issued a formal update on the trial. “There was one patient death early in the
When CEO Randall Stephenson told analysts that AT&T will use newly acquired satellite TV broadcaster DirecTV to grow “subscribers, revenue and earnings,” it was telling that he put subscribers first. “As we begin to work through the cross-selling opportunities, we think there is very strong upside to the synergies,” Stephenson said at an analysts meeting Wednesday in Dallas. AT&T (T) quickly stepped up marketing once its DirecTV Group purchase
The talk of possibly putting itself on the market, which propelled Salesforce.com’s (CRM) stock to a record high above 78 in April, has subsided, and the cloud computing pioneer has stayed roughly flat ever since. As rumors swirled that Salesforce might be the object of desire for such suitors/rivals as Oracle (ORCL), Microsoft (MSFT) and SAP (SAP), Salesforce has been able to beat Wall Street earnings estimates. That’s been the case for each of